Nasus Pharma Ltd.
NSRX | AMEX
$3.14
+$0.07 (+2.28%)
Nov 2, 2026, 10:52 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -6.04M | -3.02M | -1.24M | -408.5K | -408.5K | -297.5K | -297.5K | -241.5K | -241.5K | -295.5K | -295.5K | -278K | -278K |
Interest Income | 128K | n/a | 23.58K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -5.95M | -2.97M | -1.39M | -597K | -597K | -333.5K | -333.5K | -442.5K | -442.5K | -410.5K | -410.5K | -92K | -92K |
Net Income | -5.94M | -2.97M | -1.39M | -626K | -626K | -330.5K | -330.5K | -435.5K | -435.5K | -418.5K | -418.5K | -107K | -107K |
Selling & General & Admin | 3.45M | 1.73M | 646.7K | 264K | 264K | 214K | 214K | 157.5K | 157.5K | 126.5K | 126.5K | 163.5K | 163.5K |
Research & Development | 2.59M | 1.29M | 588.95K | 144.5K | 144.5K | 83.5K | 83.5K | 84K | 84K | 169K | 169K | 114.5K | 114.5K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.04M | 3.02M | 1.24M | 408.5K | 408.5K | 297.5K | 297.5K | 241.5K | 241.5K | 295.5K | 295.5K | 278K | 278K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.04M | 3.02M | 1.24M | 408.5K | 408.5K | 297.5K | 297.5K | 241.5K | 241.5K | 295.5K | 295.5K | 278K | 278K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.07M | 11M | 9.02M | 7.72M | 7.72M | 7.1M | 7.1M | 6.7M | 6.7M | 7.02M | 7.02M | 2.39M | 2.39M |
Shares Outstanding (Diluted) | 11.07M | 11.07M | 9.02M | 7.36M | 7.36M | 7.17M | 7.17M | 6.89M | 6.89M | 6.89M | 6.89M | 6.89M | 6.89M |
EPS (Basic) | -0.54 | -0.27 | -0.15 | -0.08 | -0.08 | -0.05 | -0.05 | -0.06 | -0.06 | -0.06 | -0.06 | -0.01 | -0.01 |
EPS (Diluted) | -0.54 | -0.27 | -0.15 | -0.08 | -0.08 | -0.05 | -0.05 | -0.07 | -0.07 | -0.06 | -0.06 | -0.04 | -0.04 |
EBITDA | -5.95M | n/a | -1.24M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EBIT | -5.95M | -3.02M | -1.24M | -408.5K | -408.5K | -297.5K | -297.5K | -241.5K | -241.5K | -295.5K | -295.5K | -278K | -278K |
Depreciation & Amortization | n/a | 3.02M | n/a | 408.5K | 408.5K | 297.5K | 297.5K | 241.5K | 241.5K | 295.5K | 295.5K | 278K | 278K |
Add to Watchlist
Select watchlists to add or remove NSRX